By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Global Alliance For TB Drug Development 

80 Broad Street, 31st Floor

New York   New York  10004  U.S.A.
Phone: 212-227-7540 Fax: 212-227-7541


SEARCH JOBS








Company News
Global Alliance For TB Drug Development Release: The Private Market for Tuberculosis Drugs: Big and Messy, but a Necessary Partner in Stopping the TB 5/5/2011 10:00:17 AM
Global Alliance For TB Drug Development Release: New Potential TB Drugs to be Investigated Against Multiple Neglected Diseases 7/7/2010 11:23:27 AM
InnoCentive, Inc. Release: Two InnoCentive Solvers Win $40,000 for Devising New Methods to Cost-Effectively Manufacture Tuberculosis Drug Candidate 12/4/2008 10:27:57 AM
Dr. Mel Spigelman, Director of Synergy Pharmaceuticals, Appointed President and CEO of Global Alliance For TB Drug Development 10/15/2008 9:18:58 AM
Global Alliance For TB Drug Development Receives Pledge of up to $40 Million from USAID 10/13/2008 10:46:21 AM
Global Alliance For TB Drug Development Appoints First Chief Administrative Officer 8/27/2008 9:12:09 AM
Novartis Institute For Tropical Diseases (NVS) and Global Alliance For TB Drug Development Announce Five-Year Collaboration Targeted to Accelerate TB Treatment R&D 6/24/2008 9:23:23 AM
Global Alliance For TB Drug Development Appoints Veteran Pharmaceutical Executive as New Chief Executive 3/5/2008 8:46:19 AM
GlaxoSmithKline (GSK) and Global Alliance For TB Drug Development Renew Tuberculosis Drug Discovery Program 1/24/2008 8:27:54 AM
Cumbre Pharmaceuticals And Global Alliance For TB Drug Development Announce Partnership To Develop New Agents For Tuberculosis Therapy 9/27/2006 10:47:14 AM
123
//-->